Trial · NCT07126639
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
NCT07126639, Not applicable, Not yet recruiting, Wuhan Pulmonary Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis. Trials, record NCT07126639. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07126639
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
- NCT number
- NCT07126639
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Wuhan Pulmonary Hospital
- Conditions
- Efficacy and Safety
- Interventions
- bedaquiline, Pretomanid (Pa), linezolid, Moxifloxacin (M), Delamanid (D), Levofloxacin, clofazimine
- First posted
- 2025-08-17
- Last updated
- 2025-08-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Favorable outcomes during the treatment period | From the initiation of treatment until the 28th week. | Cure: Completing 80% or more of the medication dosage as required by the protocol within 28 weeks after the start of the research treatment, with no evidence of treatment failure, and the Mycobacterium tuberculosis (MTB) cultures of the last two sputum specimens (collection interval ≥ 14 days) at the end of treatment being negative. Treatment completion: Completing more than 80% of the medication dosage as required by the protocol within 28 weeks after the start of the research treatment, with no evidence of treatment failure, but without evidence that the MTB cultures of two sputum specimens collected at an interval of at least 14 days are negative. |
| Secondary | Favorable outcomes during the follow - up period after treatment | From the beginning of the treatment until 72 weeks. | Cure: Negative Mycobacterium tuberculosis (MTB) sputum culture at 72 weeks after enrollment. Negative sputum culture at the last visit before loss to follow - up: If the patient is lost to follow - up before 72 weeks after enrollment and the last MTB sputum culture before loss to follow - up is negative. |
| Secondary | Favorable outcomes with an extended follow - up period | Follow - up was conducted until 108 weeks after enrollment. | Cure: Negative mycobacterium tuberculosis (MTB) sputum culture at 108 weeks after enrollment. Negative sputum culture at the last visit before loss to follow - up: If the patient is lost to follow - up before 108 weeks after enrollment and the last MTB sputum culture before loss to follow - up is negative. |
| Secondary | Unfavorable outcome | From the time of enrollment until the 108th week of follow - up | Death: Occurrence of death due to any cause. Drug replacement: Permanent replacement or addition of at least one medication due to any reason, excluding adjustments based on baseline drug susceptibility. Drug discontinuation: Discontinuation of at least one medication for more than 14 consecutive days within 16 weeks after the initiation of the study treatment for any reason; after 16 weeks, if sputum conversion has occurred, drug discontinuation is not considered an adverse outcome. Treatment failure: At the end of treatment, the results of Mycobacterium tuberculosis (MTB) culture from the last two independently collected sputum specimens (with a collection interval of ≥14 days) are positive. Extended treatment: Continuation of anti - tuberculosis treatment after 28 weeks from the start of treatment. Loss to follow - up: A study participant is considered lost to follow - up if they miss two consecutive follow - up visits within 16 weeks after the initiation of the study treatment; af |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07126639
GET https://conductscience.org/api/trials/v1/NCT07126639/registered